Epigallocatechin gallate acts synergistically in combination with cisplatin and designed trans -palladiums in ovarian cancer cells

Anticancer Research

Volumn 32, Issue 11, 2012, Pages 4851-4860

  Mazumder, Mohammed Ehsanul Hoque ^a   Beale, Philip ^b   Chan, Charles ^b   Yu, Jun Q ^a   Huq, Fazlul ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

Cisplatin; Drug combination; Drug resistance; Epigallocatechin 3 gallate; Ovarian cancer; Synergism; Trans palladiums

Indexed keywords

BIS(2 HYDROXYPYRIDINE)DICHLOROPALLADIUM; BIS(3 HYDROXYPYRIDINE)DICHLOROPALLADIUM; BIS(4 HYDROXYPYRIDINE)DICHLOROPALLADIUM; CISPLATIN; EPIGALLOCATECHIN GALLATE; PALLADIUM; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; COMPARATIVE EFFECTIVENESS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG ANTAGONISM; DRUG DNA BINDING; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IC 50; OVARY CANCER; PRIORITY JOURNAL; R FACTOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CATECHIN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DNA ADDUCTS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PALLADIUM;

EID: 84872665651     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Helm C and States J: Enhancing the efficacy of cisplatin in ovarian cancer treatment - could arsenic have a role. J Ovarian Res 2(1): 1-7, 2009.
2. Zhang N, Zhang H, Xia L, Zheng Y, Yu Y and Zhu Y: NSC606985 induces apoptosis, exerts synergistic effects with cisplatin, and inhibits hypoxia-stabilized HIF-1α protein in human ovarian cancer cells. Cancer Lett 278(2): 139-144, 2009.
3. Schuijer M and Berns EMJJ: TP53 and ovarian cancer: Human Mutation 21(3): 285-291, 2003.
4. Solomon L, Ali S, Banerjee S, Munkarah A, Morris R and Sarkar F: Sensitization of ovarian cancer cells to cisplatin by genistein: the role of NF-kappaB. J Ovarian Res 1(1): 9, 2008.
5. Gao E, Liu C, Zhu M, Lin H, Wu Q and Liu L: Current development of Pd(II) complexes as potential antitumor agents. Current Med Chem 9(3): 356-368, 2009.
6. Huq F, Tayyem H, Beale P and Yu JQ: Studies on the activity of three palladium(II) compounds of the form: trans- PdL2Cl2 where L=2-hydroxypyridine, 3-hydroxypyridine, and 4-hydroxypyridine. J Inorganic Biochem 101(1): 30-35, 2007.
7. Travnicek Z, Szucova L and Popa I: Synthesis, characterization and assessment of the cytotoxic properties of cis and trans- [PdL2Cl2] complexes involving 6-benzylamino-9-isopropylpurine derivatives. J Inorganic Biochem 101(3): 477-492, 2007.
8. Abu-Surrah AS, Abu Safieh KA, Ahmad IM, Abdalla MY, Ayoub MT and Qaroush AK: New palladium(II) complexes bearing pyrazole-based Schiff base ligands: Synthesis, characterization and cytotoxicity. Eur J Med Chem 45(2): 471-475, 2010.
9. Shi CY, Gao EJ, Ma S, Wang ML and Liu QT: Synthesis, crystal structure, DNA-binding and cytotoxicity in vitro of novel cis-Pt(II) and trans-Pd(II) pyridine carboxamide complexes. Bioorg Med Chem Lett 20(24): 7250-7254, 2010.
10. Huq F, Tayyem H, Abdullah A, Beale P and Fisher K: Synthesis and characterization and binding of amine-palladium (II) complexes and their interaction with DNA. Asian J Chem 8(1): 65-78, 2006.
11. Arafa ESA, Zhu Q, Barakat BM, Wani G, Zhao Q and El-Mahdy MA: Tangeretin sensitizes cisplatin-resistant human ovarian cancer cells through downregulation of phosphoinositide 3-kinase/AKT signaling pathway. Cancer Res 69(23): 8910-8917, 2009.
12. Garg AK, Buchholz TA, Aggarwal BB, Garg AK, Buchholz TA and Aggarwal BB: Chemosensitization and radiosensitization of tumors by plant polyphenols. Antiox Redox Signal 7(11-12): 1630-1647, 2005.
13. HemaIswarya S, Doble M and Doble M: Potential synergism of natural products in the treatment of cancer. Phytotherapy Res 20 (4): 239-249, 2006.
14. Chan MM and Fong D: Overcoming drug resistance by phytochemicals. In: Drug Resistance in Cancer Cells. Siddik ZH and Mehta K (eds.). New York, Springer Science+Business Media, LLC., pp. 315-342, 2009.
15. Dong Z, Ma WY, Huang C and Yang CS: Inhibition of tumor promoter-induced activator protein 1 activation and cell transformation by tea polyphenols, (-)-epigallocatechin gallate, and theaflavins. Cancer Res 57(19): 4414-4419, 1997.
16. Singh BN, Shankar S and Srivastava RK: Green tea catechin, epigallocatechin-3-gallate (EGCG): Mechanisms, perspectives and clinical applications. Biochem Pharmacol 82(12): 1807-1821, 2011.
17. Carlson JR, Bauer BA, Vincent A, Limburg PJ and Wilson T: Reading the tea leaves: Anticarcinogenic properties of (-)- epigallocatechin-3-gallate. Mayo Clinic Proc 82(6): 725-732, 2007.
18. Suganuma M, Okabe S, Kai Y, Sueoka N, Sueoka E and Fujiki H: Synergistic effects of (-)-epigallocatechin gallate with (-)- epicatechin, sulindac, or tamoxifen on cancer-preventive activity in the human lung cancer cell line PC-9. Cancer Res 59(1): 44-47, 1999.
19. Suganuma M, Kurusu M, Suzuki K, Tasaki E and Fujiki H: Green tea polyphenol stimulates cancer preventive effects of celecoxib in human lung cancer cells by up-regulation of GADD153 gene. Int J Cancer 119(1): 33-40, 2006.
20. Yunos NM, Beale P, Yu JQ and Huq F: Synergism from sequenced combinations of curcumin and epigallocatechin-3- gallate with cisplatin in the killing of human ovarian cancer cells. Anticancer Res 31(4): 1131-1140, 2011.
21. 2]. Indian J Chem 8: 193-194, 1970.
22. Kauffman G and Cowan D: Cis- and trans- dichlorodiammineplatinum(II). Inorg Syn 7: 239-245. 1963.
23. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65(1-2): 55-63, 1983.
24. Chou TC: Relations between inhibition constants and fractional inhibition on enzyme-catalyzed reactions with different numbers of reactants, different reaction mechanisms, and different types and mechanisms of inhibition. Mol Pharmacol 10(2): 235-247, 1974.
25. Chou TC: Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J Theor Biol 59(2): 253-276, 1976.
26. Chou TC and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enz Reg 22: 27-55, 1984.
27. Di Blasi P, Bernareggi A, Beggiolin G, Piazzoni L, Menta E and Formento ML: Cytotoxicity, cellular uptake and DNA binding of the novel trinuclear platinun complex BBR 3464 in sensitive and cisplatin resistant murine leukemia cells. Anticancer Res 18(4C): 3113-3117, 1998.
28. Roberts JD, Peroutka J, Beggiolin G, Manzotti C, Piazzoni L and Farrell NP: Comparison of cytotoxicity and cellular accumulation of polynuclear platinum complexes in L1210 murine leukemia cell lines. J Inorg Biochem 77(1-2): 47-50, 1999.
29. Bowtell DDL: Rapid isolation of eukaryotic DNA. Anal Biochem 162(2): 463-465, 1987.
30. Holford J, Beale PJ, Boxall FE, Sharp SY and Kelland LR: Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines. Eur J Cancer 36(15): 1984-1990, 2000.
31. 2 where L=2-hydroxypyridine, 3-hydroxypyridine, imidazole, and imidazo(1,2- alpha)pyridine. Eur J Med Chem 39(8): 691-697, 2004.
32. 2, where L=2- hydroxypyridine, imidazole, 3-hydroxypyridine and imidazo(1,2- alpha)pyridine. J Inorg Biochem 98(8): 1261-1270, 2004.
33. Aris SM, Gewirtz DA, Ryan JJ, Knott KM and Farrell NP: Promotion of DNA strand breaks, interstrand cross-links and apoptotic cell death in A2780 human ovarian cancer cells by trans-platinum planar amine complexes. Biochem Pharmacol 73(11): 1749-1757, 2007.
34. Huh SW, Bae SM, Kim Y-W, Lee JM, Namkoong SE and Lee IP: Anticancer effects of (-)-epigallocatechin-3-gallate on ovarian carcinoma cell lines. Gynecol Oncol 94(3): 760-768, 2004.
35. Yan C, Yang J, Shen L and Chen X: Inhibitory effect of epigallocatechin gallate on ovarian cancer cell proliferation associated with aquaporin 5 expression. Arch Gynecol Obstet 285(2): 459-467. 2012.
36. Rao SD and Pagidas K: Epigallocatechin-3-gallate, a natural polyphenol, inhibits cell proliferation and induces apoptosis in human ovarian cancer cells. Anticancer Res 30(7): 2519-2523, 2010.
37. Azam S, Hadi N, Khan NU and Hadi SM: Prooxidant property of green tea polyphenols epicatechin and epigallocatechin-3- gallate: Implications for anticancer properties. Toxicol In Vitro 18(5): 555-561, 2004.
38. Chan MM, Soprano KJ, Weinstein K and Fong D: Epigallocatechin-3-gallate delivers hydrogen peroxide to induce death of ovarian cancer cells and enhances their cisplatin susceptibility. J Cell Physiol 207(2): 389-96, 2006.
39. Johnson MK and Loo G: Effects of epigallocatechin gallate and quercetin on oxidative damage to cellular DNA. Mutat Res DNA Repair 459(3): 211-218, 2000.
40. Dou Q, Landis-Piwowar K, Chen D, Huo C, Wan S and Chan T: Green tea polyphenols as a natural tumour cell proteasome inhibitor. Inflammopharmacol 16(5): 208-212, 2008.
41. Yang H, Landis-Piwowar K, H Chan T, and P Dou Q: Green tea polyphenols as proteasome inhibitors: Implication in chemoprevention. Curr Cancer Drug Targets 11(3): 296-306, 2011.
42. Al-Eisawi Z, Beale P, Chan C, Yu JQ and Huq F: Modulation of cisplatin cytotoxicity due to its combination with bortezomib and the nature of its administration. Anticancer Res 31(9): 2757-2762, 2011.
43. Jandial DD, Farshchi-Heydari S, Larson CA, Elliott GI, Wrasidlo WJ and Howell SB: Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1. Clinical Cancer Res 15(2): 553-560, 2009.
44. Stewart DJ: Mechanisms of resistance to cisplatin and carboplatin. Crit Revs Oncol Hematol 63 (1): 12-31, 2007.
45. Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22(47): 7265-7279, 2003.
46. Nakanishi C and Toi M: Nuclear factor-[kappa]B inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5(4): 297-309, 2005.
47. Ferrandina G, Lauriola L, Zannoni GF, Fagotti A, Fanfani F and Legge F: Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol 13(8): 1205-1211, 2002.
48. Peng DJ, Wang J, Zhou JY and Wu GS: Role of the AKT/mTOR survival pathway in cisplatin resistance in ovarian cancer cells. Biochem Biophys Res Communic 394(3): 600-605, 2010.
49. Oiso S, Ikeda R, Nakamura K, Takeda Y, Akiyama S and Kariyazono H: Involvement of NF-kappaB activation in the cisplatin resistance of human epidermoid carcinoma KCP-4 cells. Oncol Rep 28(1): 27-32, 2012.
50. Tang FY, Nguyen N and Meydani M: Green tea catechins inhibit VEGF-induced angiogenesis in vitro through suppression of VE-cadherin phosphorylation and inactivation of Akt molecule. Inter J Cancer 106(6): 871-878, 2003.
51. Gupta S, Hussain T and Mukhtar H: Molecular pathway for (-)- epigallocatechin-3-gallate-induced cell cycle arrest and apoptosis of human prostate carcinoma cells. Arch Biochem Biophys 410(1): 177-185, 2003.
52. Peng G, Dixon DA, Muga SJ, Smith TJ and Wargovich MJ: Green tea polyphenol (-)-epigallocatechin-3-gallate inhibits cyclooxygenase-2 expression in colon carcinogenesis. Mol Carcinogen 45(5): 309-319, 2006.
53. Khan N, Afaq F, Saleem M, Ahmad N and Mukhtar H: Targeting multiple signaling pathways by green tea polyphenol (-)- epigallocatechin-3-gallate. Cancer Res 66(5): 2500-2505, 2006.
54. Banerjee S, Zhang Y, Wang Z, Che M, Chiao PJ and Abbruzzese JL: In vitro and in vivo molecular evidence of genistein action in augmenting the efficacy of cisplatin in pancreatic cancer. Inter J Cancer 120 (4): 906-917, 2007.
55. Jobin C, Bradham CA, Russo MP, Juma B, Narula AS and Brenner DA: Curcumin blocks cytokine-mediated NF-κB activation and proinflammatory gene expression by inhibiting inhibitory factor I-κB kinase activity. J Immunol 163 (6): 3474-3483, 1999.
56. Plummer SM, Holloway KA, Manson MM, Munks RJ, Kaptein A and Farrow S: Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signaling complex. Oncogene 18(44): 6013-6020, 1999.
57. Jones NA, Turner J, McIlwrath AJ, Brown R and Dive C: Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between BAX and BAK up-regulation and the functional status of p53. Mol Pharmacol 53(5): 819-826, 1998.
58. Ray S, Mohan R, Singh JK, Samantaray MK, Shaikh MM and Panda D: Anticancer and antimicrobial metallopharmaceutical agents based on palladium, gold, and silver N-heterocyclic carbene complexes. J Am Chem Soc 129(48): 15042-15053, 2007.